key: cord-0766135-wn8rtykg
authors: Scullen, Tyler; Keen, Joseph; Mathkour, Mansour; Dumont, Aaron S.; Kahn, Lora
title: COVID-19 associated encephalopathies and cerebrovascular disease: the New Orleans experience
date: 2020-05-28
journal: World Neurosurg
DOI: 10.1016/j.wneu.2020.05.192
sha: 6807029832870d756d4b5b8da6c3e5f69efa2248
doc_id: 766135
cord_uid: wn8rtykg

nan

The coronavirus disease 2019 pandemic that is due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a dramatic impact on healthcare systems 1 . While the majority of patients experience mild disease, a subset develops complex multi-organ failure 1 . Confirmed disease afflicts 2.92 million patients globally as of April 26th, 2020 with 829,000 recovered and an associated mortality of 204,000 (5.2%) 2 .

SARS-CoV-2 is a member of the coronaviridae family, composed of enveloped positive sense single stranded ribonucleic acid (+ssRNA) viruses typically responsible for a spectrum of respiratory and gastrointestinal diseases, but with occasional neurotropism 1 Middle East Respiratory Syndrome coronavirus (MERS-CoV), which have demonstrated the ability to produce neuromuscular and neurological symptoms [3] [4] [5] [6] [7] [8] . Experimental studies suggest early brainstem involvement and secondary damage via exaggerated host immune responses 9, 10 .

Additionally, known homologues such as the human coronaviruses OC34 and 229E (HcoV-OC34 and HcoV-229E) have been detected in brain tissue of multiple sclerosis patients, and

human T-cell lines have been found to cross-react with myelin basic protein and viral antigens, suggesting molecular mimicry and a potential pathogenesis for central nervous system (CNS) injury 11,12 . Emerging evidence demonstrates that SARS-CoV-2 is associated with neurological disease [13] [14] [15] , including meningoencephalitis, virus-associated necrotizing encephalopathy similar to the influenza-associated encephalopathy (IAE), and secondary cytokine-induced acute necrotizing encephalopathy syndromes observed in members of the orthomyxoviridae family such as the hemagglutinin 1 neuraminidase 1 influenza virus (H1N1) [13] [14] [15] . These findings highlight the additional challenge facing the neurosciences during this pandemic, 16 We describe and categorize the CNS manifestations observed in critical COVID-19 patients, who were admitted on one day to our tertiary academic center.

This is a single center retrospective cross-sectional analysis of all patients admitted to our Based on imaging, patients were grouped into one of three informal categories. Patients were categorized as having "COVID-19 associated encephalopathy" if they had either scalp electroencephalography (EEG) showing either generalized encephalopathy or epileptic encephalopathy as well as changes on head computed tomography (CT) and/or magnetic resonance imaging (MRI). Patients were designated "COVID-19 associated acute necrotizing encephalopathy" if they demonstrated significant changes in midline and periventricular structures on MRI and/or CT and had evidence of hemorrhagic conversion on either gradient echo (GRE) or susceptibility weight imaging (SWI) MRI sequences. An informal diagnosis of "COVID-19 associated vasculopathy" was given to patients with evidence of acute ischemic stroke affecting large vessel territories with or without evidence of large vessel occlusion (LVO) on CT or MR angiography (CTA and MRA).

Diagnostic criteria for the above categorizations were derived from existing defined viral associated disease presentations, such as IAE [13] [14] [15] , influenza associated acute necrotizing encephalopathy [13] [14] [15] , Human Immunodeficiency Virus (HIV) associated vasculitis 31 , and Human Herpes Virus 3 (VZV) associated vasculopathy 31 .

A total of 76 patients were admitted on April 22 nd to one of several repurposed respiratory ICUs (RICU), who were in critical condition and confirmed to have COVID-19. Of these, 27 patients (35.5%) had evidence of new onset neurological disease, which ranged from mild headache and dysgeusia to severe focal deficits (Table 1 ). All but one patient with neurological involvement developed altered mental status during their hospital course (96.3%).

Eight (30%) patients tested positive for SARS-CoV-2 on multiple interval tests. As patients without active disease as well as those who had confirmed negative RT-PCR and/or NAAT testing as well as absence of clinical evidence of COVID-19 at the time of neurological involvment, and no recurrent infections were observed, zero patients tested negative. Positive tests were documented on 37 occasions, eight (22%) of which were confirmed via NAAT and the remainder via RT-PCR. As of April 23 rd 2020, three patients (11%) have expired.

Patients had a mean age of 59.8 years (range 35-91 years) and 48% were female. The vast majority of patients had an underlying medical condition, with hypertension (63%), diabetes mellitus type 2 (DM2) (52%), obesity (26%), and chronic kidney disease (CKD) (22%) being the most common (Table 1) . During their clinical course, 51.8% of patients suffered secondary infection, ranging from bacteremia (22%), urinary tract infection (15%), bacterial pneumonia (11%) to fungemia (4%). Patients with neurological manifestations had a higher proportion of DM2 (52% vs 40%) but this did not reach statistical significance (p=0.32).

Seventy one percent of included patients were imaged with two or more modalities. All included patients underwent non-contrast CT of head, ten patients of which were scanned for new onset focal deficit and thirteen for persistent AMS in the absence of sedatives. An additional eight patients underwent MRI for furher investigation of suspected large territory infarct, hemorrhagic, or encephalitic process. Three patients underwent CTA without MRI to acutely evaluate suspected LVO and another four underwent MRA in addition to non-vascular MR for concern for ongoing vasculopathy. Thirteen patients received continuous EEG for pronounced encephalopathy not explained by previous CT alone (n=9) or combined CT and MRI (n=4) findings.

A total of 23 patients (85%) demonstrated radiographic or electrographic evidence of neurologic disease: 63% had positive findings on CT, 30% on MRI, and 15% on non-invasive vascular imaging. Forty-four percent of included patients (100% who received EEG) demonstrated abnormal findings on EEG. CT findings most often included subacute ischemic strokes, diffuse hypoattenuation, subcortical parenchymal hemorrhages, and focal hypodensities in deep structures ( Table 2 ). MRI findings often resembled viral encephalitis with diffuse involvement of the deep white matter, corpus callosum, and basal ganglia.

Vascular imaging was obtained most often to rule out acute ischemic stroke. Four large territory infarcts were discovered on MRI -three involving an extensive middle cerebral artery (MCA) territory and one involving the posterior cerebral artery (PCA) territory. Of the posterior circulation strokes, one study demonstrated LVO of the PCA P2B segment that corresponded with evolving infarct. The other three studies showed irregular proximal focal stenosis of the supraclinoidal internal carotid artery (ICA), particularly at the area of the terminus, with patent anterior circulation vasculature. (Table 2) .

EEG on affected patients yielded a high proportion of generalized encephalopathy, with one patient showing activity suggestive of non-convulsive status epilepticus (NCSE) ( Table 2 ).

Encephalopathy typically consisted of irregular slowing with delta and theta frequency oscillations.

Twenty patients (74%) were diagnosed with COVID-19 associated encephalopathy, two (7%) with COVID-19 associated acute necrotizing encephalopathy, and five (19%) with COVID-19 associated vasculopathy. Of the last group, one patient had evidence of LVO while the other four had focal stenosis at the ICA terminus and distal supraclinoid segments with patent distal vasculature. 

Evolving evidence concerning critically hospitalized patients with confirmed COVID-19 links co-morbidities of DM2, hypertension, chronic obstructive pulmonary disease (COPD), CKD, obesity, and cardiovascular disease with an increased risk of more severe disease course and multi-system effects [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . Given that the above co-morbidities are seen in patients undergoing treatment for neurological conditions, particularly in the context of ischemic occlusive and hemorrhagic cerebrovascular disease, neurological and neurosurgical patients at heightened risk [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . In contrast to the typical bimodal patterns of age distribution of moderate and severe viral disease, data has demonstrated that increased age was significantly associated with greater odds of mortality for every additional year of life [20] [21] [22] . Patients in our cohort carried a high proportion of co-morbidities and were relatively young. It is possible that the age phenomenon is confounded by the presence of complex multi-systemic disease states such DM2 and CKD, as every year of life increases the probability of developing a comorbid disease. We hypothesize that our patient population's high rate of comorbid disease is responsible for the more serious course of illness being experienced.

It is intuitive that severe strain on pulmonary function via acute respiratory distress syndrome (ARDS) would exacerbate preexisting systemic disease via various pathophysiological pulmonary mechanisms and accelerate such conditions [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . Furthermore, a preexisting history of ischemic or hemorrhagic stroke has been demonstrated to be a significant risk factor for the development of ARDS in the neurointensive setting [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . Severe COVID-19 carries an association of vascular thrombosis 23 . It thus becomes critical to accurately characterize disease pathophysiology to rule out direct injury secondary to viral infection from consequent systemic pathophysiology.

Much of SARS-CoV-2 pathophysiology has been derived from literature concerning SARS-CoV-1 24-30 . Both viruses have been shown to enter lower respiratory epithelium via attachment to the angiotensin converting enzyme 2 receptor (ACE2R) [24] [25] [26] [27] [28] [29] [30] . While ACE2R is found primarily in lung alveolar epithelium, it is present on the surface of CNS neurons, suggesting potential neurotropism [24] [25] [26] [27] [28] [29] [30] . An axodendritic trans-synaptic route has been reported as a potential mechanism for CNS dissemination 9 Xa unless otherwise contraindicated.

The increased prevalence of acute cerebrovascular disease in patients with severe infection is thought to be related to elevated D-dimer levels, which have been previously shown to correlate with unfavorable outcomes in stroke patients 33 . Furthermore, cerebrovascular disease is a known predisposing factor for the development of ARDS in a neurocritical care setting 33 .

While there are no specific guidelines concerning preexisting stroke or elevated D-dimer in the setting of COVID-19, it is easy to speculate that these patients likely have an increased likelihood of progressing to ARDS and warrant increased vigilance in monitoring disease course. In our cohort of COVID-19 patients, stroke involved either focal subcortical lobar ICH, large territory anterior circulation infarcts in the presence of focal ICA terminus stenosis without LVO, or both. Although COVID-19 is known to induce thrombosis-associated complications, including stroke, reports did not confirm LVO to be the actual etiology 23 

We acknowledge our report is limited by the restrospective nature of analysis and our limiting inclusion criteria to patients actively admitted to our center in critical condition with confirmed COVID-19. Future investigations will seek to expand our data in a prospective manner for all patients with confirmed SARS-CoV-2 postive assay. Likewise at the time of data collection, we were not actively evalauting patient CSF for the presence of viral gentic material.

Prospective CSF analysis will also be included in ongoing studies as deliniation of associated clinical factors and chronology of positive viral tests in CSF as compared to other mediums is critical in understanding disease pathbiology and transmissiblity. Furthermore, as neurological disease in COVID-19 is actively being characterized, we did not have a specific imaging protocol for such patients and all patients were imaged secdonary to clinical findings. As such not all patients received combined CT, EEG, vascular studies, and MRI, potentially masking relevant radiographic findings.

As the SARS-CoV-2 pandemic continues, we increasingly appreciate the neurological N denotes total number of patients with documentation of said finding, % is relative to all critical COVID-19 patients with clear neurological involvement. N denotes total number of patients with documentation of said finding, % is relative to all critical COVID-19 patients with clear neurological involvement. DWI denotes abnormality on diffuse weighted imaging, ep2d_tra_hemo gradient echo imaging, FLAIR fluid-attenuated inversion recovery, MP-RAGE magnetization prepared -rapid gradient echo, and SWI susceptibility weighed imaging. ICA denotes internal carotid artery, PCA posterior cerebral artery.

A Novel Coronavirus from Patients with Pneumonia in China

Coronavirus disease 2019 (COVID-19): situation report

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Neurological Complications during Treatment of Middle East Respiratory Syndrome

Neuromuscular disorders in severe acute respiratory syndrome

Peripheral nerve disease in SARS:: report of a case

Neurological Complications of Middle East Respiratory Syndrome Coronavirus: A Report of Two Cases and Review of the Literature

Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV)

The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients

Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System? Viruses

Detection of coronavirus RNA and antigen in multiple sclerosis brain

Long-term human coronavirus-myelin crossreactive T-cell clones derived from multiple sclerosis patients

Neurological Complications of Coronavirus Disease (COVID-19): Encephalopathy. Cureus

COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: CT and MRI Features

A first Case of Meningitis/Encephalitis associated with SARS-Coronavirus-2

Preparing a neurology department for SARS-CoV-2 (COVID-19): Early experiences at Columbia University Irving Medical Center and the New York Presbyterian Hospital

High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation

Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission

Kidney disease is associated with in-hospital death of patients with COVID-19

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

COVID-19) -United States

Similarity in Case Fatality Rates (CFR) of COVID-19/SARS-COV-2 in Italy and China

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

A pneumonia outbreak associated with a new coronavirus of probable bat origin

ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Potential harmful effects of discontinuing ACEinhibitors and ARBs in COVID-19 patients

Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension

Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Universal Precautions. StatPearls. Treasure Island (FL)

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

Hypercoagulability of COVID-19 patients in Intensive Care Unit. A Report of Thromboelastography Findings and other Parameters of Hemostasis

D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19

Acute Pulmonary Embolism in COVID-19 Patients on CT Angiography and Relationship to D-Dimer Levels

Thromboembolic risk and anticoagulant therapy in COVID-19 patients: Emerging evidence and call for action

Cytomegalovirus Coinfection Is Associated with Increased Vascular-Homing CD57(+) CD4 T Cells in HIV Infection

Zoster Sine Herpete Masquerading as Central Nervous System Vasculitis

Kawasaki diseaseassociated MERS: pathological insights from SPECT findings

Effects of underlying cerebrocardiovascular diseases on the incidence of critical conditions and multiple organs dysfunction syndrome in severe acute respiratory syndrome cases

Abbreviations (+)ssRNA: Positive Sense Single Stranded Ribonucleic Acid ADEM: Acute Disseminated Encephalomyelitis CKD: Chronic Kidney Disease CNS: Central Nervous System COVID-19: Coronavirus disease 2019 CRRT: Continuous Renal Replacement Therapy CSF: Cerebrospinal Fluid DM2: Diabetes Mellitus Type 2 EEG: scalp Electroencephalography FLAIR: Fluid Attenuated Inversion Recovery GRE: Gradient Echo HCoV: Human Coronavirus IAE: Influenza Associated Encephalopathy ICH: Intracerebral Hemorrhage ICA: Internal Carotid Artery LVO: Large Vessel Occlusion MCA: Middle Cerebral Artery MERS-CoV: Middle Eastern Respiratory Syndrome Coronavirus NAAT: Nucleic Acid Amplification Technique NCSE: Non-convulsive Status Epilepticus PCA: Posterior Cerebral Artery PLEX: Plasma Exchange RICU: Respiratory Intensive Care Unit RT-PCR: Reverse Transcriptase Polymerase Chain Reaction SARS-CoV-1: Severe Acute Respiratory Distress Syndrome Coronavirus 1

Severe Acute Respiratory Distress Syndrome Coronavirus 2 SWI: Susceptibility Weighted Imaging VZV: Varicella Zoster Virus

The authors have no financial or proprietary interest in the subject matter of this article.